Get the Stockscreener App
23.85
1.19%
0.28
Pre-market:
24.61
0.76
+3.19%
Dianthus Therapeutics Inc stock is traded at $23.85, with a volume of 208.24K.
It is up +1.19% in the last 24 hours and up +15.83% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$23.57
Open:
$23.39
24h Volume:
208.24K
Relative Volume:
0.61
Market Cap:
$767.69M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-4.3028
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-1.97%
1M Performance:
+15.83%
6M Performance:
+10.42%
1Y Performance:
-17.27%
1-Day Range:
$23.39
$24.23
1-Week Range:
$22.81
$25.41
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
23.85 | 758.68M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Can swing trading help recover from Dianthus Therapeutics Inc. lossesJuly 2025 Highlights & Consistent Growth Stock Picks - Newser
Nuveen LLC Invests $1.17 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Heatmap analysis for Dianthus Therapeutics Inc. and competitorsJuly 2025 Movers & Real-Time Volume Analysis - Newser
What data driven models say about Dianthus Therapeutics Inc.’s futureMarket Rally & Verified Momentum Stock Watchlist - Newser
Published on: 2025-09-03 01:20:13 - Newser
Best data tools to analyze Dianthus Therapeutics Inc. stockQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. stock go up soonJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - Newser
Applying big data sentiment scoring on Dianthus Therapeutics Inc.Trend Reversal & Stepwise Swing Trade Plans - Newser
Combining machine learning predictions for Dianthus Therapeutics Inc.July 2025 Summary & Daily Technical Stock Forecast Reports - Newser
Technical signs of recovery in Dianthus Therapeutics Inc.Dividend Hike & AI Optimized Trading Strategy Guides - Newser
Visual trend scoring systems applied to Dianthus Therapeutics Inc.Weekly Risk Report & High Yield Equity Trading Tips - Newser
Walleye Capital LLC Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
What is Dianthus Therapeutics Inc.’s book value per shareWeekly Stock Summary & Proven Capital Preservation Tips - خودرو بانک
Is Dianthus Therapeutics Inc. in accumulation or distribution phaseMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
What’s the fair value of Dianthus Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - خودرو بانک
Is Dianthus Therapeutics Inc. in a bullish channelTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Can Dianthus Therapeutics Inc. rally from current levelsWeekly Trend Summary & AI Forecasted Stock Moves - Newser
Analyzing Dianthus Therapeutics Inc. with multi timeframe charts2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Does Dianthus Therapeutics Inc. stock benefit from AI growthM&A Rumor & Accurate Intraday Trading Signals - خودرو بانک
Can a trend reversal in Dianthus Therapeutics Inc. lead to recoveryOptions Play & Weekly Breakout Watchlists - Newser
Wellington Management Group LLP Buys 7,645 Shares of Dianthus Therapeutics, Inc. $DNTH - Defense World
Understanding Dianthus Therapeutics Inc.’s price movement2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Analyzing net buyer seller activity in Dianthus Therapeutics Inc.Trade Signal Summary & Short-Term High Return Strategies - Newser
Does Dianthus Therapeutics Inc. fit your quant trading modelEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Momentum divergence signals in Dianthus Therapeutics Inc. chartTrade Volume Summary & Precise Buy Zone Identification - Newser
Visualizing Dianthus Therapeutics Inc. stock with heatmapsWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - Newser
Is Dianthus Therapeutics Inc. trending in predictive chart modelsOil Prices & Community Supported Trade Ideas - Newser
Leading vs lagging indicators on Dianthus Therapeutics Inc. performanceEarnings Recap Summary & Precise Trade Entry Recommendations - Newser
Is Dianthus Therapeutics Inc. stock poised for growthJuly 2025 Earnings & Trade Opportunity Analysis - Newser
Real time scanner hits for Dianthus Therapeutics Inc. explained2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
How to forecast Dianthus Therapeutics Inc. trends using time seriesWeekly Trend Recap & AI Powered Trade Plan Recommendations - Newser
Using R and stats models for Dianthus Therapeutics Inc. forecastingMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Dianthus Therapeutics, Inc. $DNTH Shares Sold by Vanguard Group Inc. - Defense World
Dianthus Therapeutics Inc. Stock Flags Risk Zone in Volatility IndexWeekly Trade Summary & Safe Investment Capital Preservation Plans - beatles.ru
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):